

**Characterizing Dual Combination Therapy Use in Treatment Escalation of Hypertension: Real-World
Evidence from Multinational Cohorts**

Supplementary Online Content

Title	Page
Appendix Text. Description of IQVIA data sources	2
Appendix Table 1. Data Source Description	3
Appendix Table 2. Drug codes of 56 drug ingredients in four major antihypertensive drug classes	4
Appendix Table 3. Twelve exposure cohorts for Class vs. Class comparison	5
Appendix Figure 1. Graphical presentation of cohort definitions	6

Appendix Text. Description of IQVIA data sources

IQVIA LPD Australia

The IQVIA LPD Australia database consists of anonymized patient records collected from Patient Management software used by GPs during an office visit to document patients' clinical records. The data originates from two sources: longitudinal patient data and practice profiles where they are integrated into one common data source.

IQVIA US Ambulatory EMR

The IQVIA US Ambulatory EMR database consists of longitudinal, de-identified electronic health records originating from ambulatory clients. The data contains detailed clinical information that captures important health outcomes such as lab test results and vital signs. It also covers administered drugs including prescription and over-the-counter medicines, vaccines, large-molecule biologic therapies, route of administration, days suppl and refill information.

IQVIA Longitudinal Patient Database (LPD) France

The IQVIA OMOP Longitudinal Patient Database (LPD) France database consists of anonymized patient records collected from Patient Management software used by Doctors during an office visit to document patients' clinical records. The total database consists of 1200 GPs, 7.8 million patients, 620 specialists across 8 specialties (cardiology, neurology, psychiatry, pulmonology, gastroenterology, gynecology, diabetology & rheumatology)

IQVIA LPD Italy

LPD Italy is comprised of anonymized patient records collected from software used by GPs during an office visit to document patients' clinical records. Data coverage includes over 2M patient records with at least one visit and 119.5M prescription orders across 900 GP practices. Dates of service include from 2004 through present. Observation time is defined by the first and last consultation dates. Drugs are captured as prescription records with product, quantity, dosing directions, strength, indication and date of consultation.

Appendix Table 1. Data Source Description

Data Source	Data Type	Country/District	Time Period	No. of Patients
IQVIA LPD Australia	EHR	Australia	2006-2020	3,101,500
ePBRN SWSLHD 2019 Linked Dataset	EHR	South Western Sydney, Australia	2012-2019	139,346
Korea Ajou University School of Medicine (AUSOM) CDM	EHR	Suwon, Korea	1995-2019	3,109,677
Korea CDM of Kyung Hee University Hospital	EHR	Seoul, Korea	2008-2018	2,010,456
Khoo Teck Puat Hospital (KTPH)	EHR	Singapore	2010-2016	290,074
National University Hospital (NUH)	EHR	Singapore	2015-2018	750,270
China Jiangsu Province Hospital	EHR	China	2005-2015	6,230,000
Taiwan Taipei Medical University Clinical Research Database (TMUCRD)	EHR	Taiwan	2004-2020	3,659,572
IQVIA Ambulatory EMR	EHR	United States	2006-2020	78,526,000
IQVIA LPD France	EHR	France	1994-2020	18,118,000
IQVIA LPD Italy	EHR	Italy	2004-2020	2,209,600

*EHR = Electronic health record

Appendix Table 2. Drug codes of 56 drug ingredients in four major antihypertensive drug classes

ACEI/ARB			Beta-blocker			Calcium channel blocker			Thiazide Diuretics		
Ingredient name	RxNorm	OMOP ID	Ingredient name	RxNorm	OMOP ID	Ingredient name	RxNorm	OMOP ID	Ingredient name	RxNorm	OMOP ID
Benazepril	18867	1335471	Esmolol	49737	19063575	Diltiazem	3443	1328165	Hydrochlorothiazide	5487	974166
Captopril	1998	1340128	Celiprolol	20498	19049145	Verapamil	11170	1307863	Xipamide	11371	19010493
Cilazapril	21102	19050216	Oxprenolol	7801	19024904	Amlodipine	17767	1332418	Chlorthalidone	2409	1395058
Enalapril	3827	1341927	Labetalol	6185	1386957	Nifedipine	7417	1318853	Indapamide	5764	978555
Fosinopril	50166	1363749	Propranolol	8787	1353766	Nicardipine	7396	1318137	Metolazone	6916	907013
Imidapril	60245	19122327	Carvedilol	20352	1346823	Felodipine	4316	1353776			
Lisinopril	29046	1308216	Pindolol	8332	1345858	Nisoldipine	7435	1319880			
Moexipril	30131	1310756	Bisoprolol	19484	1338005	Isradipine	33910	1326012			
Perindopril	54552	1373225	Penbutolol	7973	1327978	Nimodipine	7426	1319133			
Quinapril	35208	1331235	Betaxolol	1520	1322081	Clevidipine	233603	19089969			
Ramipril	35296	1334456	Acebutolol	149	1319998	Nilvadipine	53692	19113063			
Trandolapril	38454	1342439	Nebivolol	31555	1314577	Mepirodipine	39879	19102106			
Zofenopril	39990	19102107	Atenolol	1202	1314002	Manidipine	29275	19071995			
Valsartan	69749	1308842	Metoprolol	6918	1307046	Nitrendipine	7441	19020061			
Candesartan	214354	1351557	Carteolol	2116	950370	Lercanidipine	135056	19015802			
Eprosartan	83515	1346686				Lacidipine	28382	19004539			
Irbesartan	83818	1347384									
Losartan	52175	1367500									
Olmesartan	321064	40226742									
Telmisartan	73494	1317640									

OMOP ID indicates the exact code used in OMOP-CDM based on RxNorm ontology. Corresponding RxNorm code to OMOP-ID are also described in this table.

ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin converting enzyme inhibitor; CDM = common data model; OMOP = observational medical outcomes partnership.

Appendix Table 3. Twelve exposure cohorts for Class vs. Class comparison

Cohort #	Dual combination*
1	ACEi/ARB + B-blocker
2	ACEi/ARB + CCB
3	ACEi/ARB + Diuretic
4	B-blocker + ACEi/ARB
5	B-blocker + CCB
6	B-blocker + Diuretic
7	CCB + ACEi/ARB
8	CCB + B-blocker
9	CCB + Diuretic
10	Diuretic + ACEi/ARB
11	Diuretic + B-blocker
12	Diuretic + CCB

* ACEi/ARB + B-Blocker denotes starting an ACEi/ARB monotherapy followed by a beta-blocker.

ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin converting enzyme inhibitor; B-blocker = beta-blocker; CCB = calcium channel blocker.

Appendix Figure 1. Graphical presentation of cohort definitions

